AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20101858 — intervention group
Group type: COMPARATOR
Intervention: Low-dose misoprostol (maximum total dose 1400 g)
Number of subjects: 60
Study 20101858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose misoprostol
Number of subjects: 60
Study 20101858 — intervention group
Group type: COMPARATOR
Intervention: Low-dose misoprostol
Number of subjects: 60
Study 16401666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day
Number of subjects: 272
Study 16401666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 16401666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 272
Study 15551047 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan, 100 mg once daily
Number of subjects: 63
Study 11269891 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 17
Study 11269891 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin
Number of subjects: 17
Study 9422295 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane/N2O
Number of subjects: 20
Study 9422295 — intervention group
Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 20
Study 8393058 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet 90 mg/kg/day infusion administered over 2 h
Number of subjects: 32
Study 8393058 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet 120 mg/kg/day infusion administered over 2 h
Number of subjects: 32
Study 2883129 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (H1 histamine receptor antagonist)
Number of subjects: 0
Study 2883129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29870736 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine (50 mg qd) + sulfadiazine (1 g tid) with folinic acid
Number of subjects: 143
Study 29870736 — intervention group
Group type: COMPARATOR
Intervention: spiramycin (1 g tid)
Number of subjects: 143
Study 29870736 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine + sulfadiazine
Number of subjects: 143
Study 29870736 — intervention group
Group type: COMPARATOR
Intervention: spiramycin
Number of subjects: 143
Study 27804255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral intervention (ABBI)
Number of subjects: 162
Study 27804255 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 162
Study 27804255 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBI
Number of subjects: 162
Study 27804255 — intervention group
Group type: COMPARATOR
Intervention: SBT
Number of subjects: 162
Study 25363170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin drops
Number of subjects: 72
Study 25363170 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin tablets
Number of subjects: 72
Study 22850757 — intervention group
Group type: EXPERIMENTAL
Intervention: Static bike group
Number of subjects: 35
Study 22850757 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill group
Number of subjects: 35
Study 22850757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 20822306 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced practice
Number of subjects: 0
Study 20822306 — intervention group
Group type: COMPARATOR
Intervention: Massed practice
Number of subjects: 0
Study 18417645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Training (IT)
Number of subjects: 11
Study 15911730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of simvastatin plus 15 g of psyllium (Metamucil) daily
Number of subjects: 68
Study 15911730 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of simvastatin plus placebo
Number of subjects: 68
Study 15911730 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of simvastatin plus placebo
Number of subjects: 68
Study 17986531 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan-neck straight catheter (SNC)
Number of subjects: 93
Study 17986531 — intervention group
Group type: COMPARATOR
Intervention: Conventional straight catheter (CS)
Number of subjects: 93
Study 17986531 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan-neck curled tip catheter (SNC)
Number of subjects: 93
Study 17986531 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan-neck straight catheter (SNS)
Number of subjects: 93
Study 10470630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% lidocaine
Number of subjects: 240
Study 10470630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% lidocaine
Number of subjects: 240
Study 10470630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% lidocaine
Number of subjects: 240
Study 10470630 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 240
Study 8602988 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (2 x 300 U/kg) and parenteral iron (2 x 200mg) with a 72 h interval
Number of subjects: 15
Study 8602988 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (2 x 300 U/kg) and parenteral iron (2 x 200mg) with a 24 h interval
Number of subjects: 15
Study 8602988 — intervention group
Group type: COMPARATOR
Intervention: Control group received parenteral iron only
Number of subjects: 15
Study 1682147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural analgesia and general anaesthesia (GAE group)
Number of subjects: 0
Study 1682147 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA group)
Number of subjects: 0
Study 1682147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 7138047 — intervention group
Group type: EXPERIMENTAL
Intervention: Test substances applied under occlusion for one month
Number of subjects: 0
Study 7138047 — intervention group
Group type: COMPARATOR
Intervention: Rabbit ear model test
Number of subjects: 0
Study 29113955 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 136
Study 29113955 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 136
Study 29113955 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 136
Study 29113955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 27164866 — intervention group
Group type: EXPERIMENTAL
Intervention: CALM tool
Number of subjects: 0
Study 27164866 — intervention group
Group type: COMPARATOR
Intervention: Manual version of CALM
Number of subjects: 0
Study 24625805 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of inactivated EV71 vaccine (160 U, 320 U, and 640 U with adjuvant and 640 U without adjuvant)
Number of subjects: 773
Study 24625805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 773
Study 22119179 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 184
Study 22119179 — intervention group
Group type: COMPARATOR
Intervention: Information-advice session
Number of subjects: 184
Study 20188087 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVIA Centaur assay
Number of subjects: 248
Study 17657384 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 70
Study 17657384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15830251 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12058997 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B immobilized fiber (PMX‐F) treatment
Number of subjects: 40
Study 12058997 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study 12058997 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 12058997 — intervention group
Group type: COMPARATOR
Intervention: Septic trauma patients before treatment
Number of subjects: 40
Study 12058997 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic trauma patients after treatment
Number of subjects: 40
Study 12058997 — intervention group
Group type: COMPARATOR
Intervention: All trauma patients
Number of subjects: 40
Study 9862248 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 10
Study 9862248 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 10
Study 9862248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7697902 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms qid)
Number of subjects: 0
Study 7697902 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg bid)
Number of subjects: 0
Study 7697902 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (1 g qid)
Number of subjects: 0
Study 7697902 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 0
Study 7697902 — intervention group
Group type: COMPARATOR
Intervention: Mucosal-coating compounds
Number of subjects: 0
Study 7697902 — intervention group
Group type: COMPARATOR
Intervention: Gastric antisecretory drugs
Number of subjects: 0
Study 7697902 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 2761586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 13
Study 2761586 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 13
Study 241932 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaket (combination of beta-receptor blocker and isosorbide dinitrate)
Number of subjects: 20
Study 241932 — intervention group
Group type: COMPARATOR
Intervention: Betadrenol (beta-receptor blocker)
Number of subjects: 20
Study 241932 — intervention group
Group type: COMPARATOR
Intervention: Isoket (isosorbide dinitrate preparation)
Number of subjects: 20
Study 241932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29584924 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk with coconut oil
Number of subjects: 60
Study 29584924 — intervention group
Group type: COMPARATOR
Intervention: Breast milk alone
Number of subjects: 60
Study 27027462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 34
Study 27027462 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 34
Study 24917586 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS walking intervention offered during rehabilitation
Number of subjects: 26
Study 24917586 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS walking intervention offered after rehabilitation
Number of subjects: 26
Study 24917586 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS walking intervention
Number of subjects: 26
Study 24917586 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 26
Study 22921680 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (n=72), administered 24 hours after rt-PA for 10 days
Number of subjects: 146
Study 22921680 — intervention group
Group type: COMPARATOR
Intervention: Non-antiplatelet therapy (n=74), received no antiplatelet therapy
Number of subjects: 146
Study 20142732 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18503929 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (group A, n = 23)
Number of subjects: 46
Study 18503929 — intervention group
Group type: COMPARATOR
Intervention: Nitric oxide (iNO) (group B, n = 23)
Number of subjects: 46
Study 15920051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin spray (20 puffs)
Number of subjects: 7
Study 15920051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin spray (5, 10, and 20 puffs)
Number of subjects: 7
Study 15920051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin spray
Number of subjects: 7
Study 15920051 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous regular insulin
Number of subjects: 7
Study 12735483 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation for two months
Number of subjects: 0
Study 12735483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9700963 — intervention group
Group type: COMPARATOR
Intervention: 0 drops of corn syrup solution
Number of subjects: 19
Study 9700963 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drop of corn syrup solution
Number of subjects: 19
Study 9700963 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 drops of corn syrup solution
Number of subjects: 19
Study 9700963 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 drops of corn syrup solution
Number of subjects: 19
Study 1818544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin and Methotrexate (CM)
Number of subjects: 41
Study 1818544 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin, Methotrexate and Prednisolone (CMP)
Number of subjects: 41
Study 6892479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine‐8‐vasopressin (LVP) 5 I.U. administered intranasally daily for 5 days
Number of subjects: 21
Study 6892479 — intervention group
Group type: COMPARATOR
Intervention: NaCl administered intranasally daily for 5 days (control group)
Number of subjects: 21
Study 31957638 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 41
Study 31957638 — intervention group
Group type: COMPARATOR
Intervention: Educational Film (EF)
Number of subjects: 41
Study 30739911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus pemetrexed–cisplatin triplet
Number of subjects: 223
Study 30739911 — intervention group
Group type: EXPERIMENTAL
Intervention: MST1 inactivation
Number of subjects: 223
Study 30739911 — intervention group
Group type: EXPERIMENTAL
Intervention: YAP silencing in MST1-depleted mesothelial cell lines
Number of subjects: 223
Study 27845156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha/theta (A/T) training (neurofeedback group, NFG)
Number of subjects: 50
Study 27806897 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable scaffold
Number of subjects: 501
Study 27806897 — intervention group
Group type: COMPARATOR
Intervention: Xience metallic stent
Number of subjects: 501
Study 24613543 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT + nimotuzumab
Number of subjects: 92
Study 24613543 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 92
Study 24613543 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + nimotuzumab
Number of subjects: 92
Study 24613543 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 92
Study 22384088 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus injection of erythropoietin, acute effects studied for 1-10 hours.
Number of subjects: 0
Study 22384088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged administration of recombinant human erythropoietin (rHuEpo) for 16 days.
Number of subjects: 0
Study 20829661 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound cleansing solution containing polihexanide and betaine
Number of subjects: 0
Study 20829661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18251141 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 46
Study 18251141 — intervention group
Group type: COMPARATOR
Intervention: Conventional
Number of subjects: 46
Study 18251141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 15734253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet (group A)
Number of subjects: 20
Study 15734253 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (group B)
Number of subjects: 20
Study 15734253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 20
Study 11489001 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin in combination with carboplatin and paclitaxel (ET-Carbo)
Number of subjects: 1281
Study 11489001 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (Carbo-T)
Number of subjects: 1281
Study 9832904 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic play (interactive puppet show)
Number of subjects: 50
Study 9832904 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 50
Study 7595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole 500 mg twice daily for 1 week
Number of subjects: 101
Study 7595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal gel 0.75% 5 g twice daily for 5 days
Number of subjects: 101
Study 7595261 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream 2% 5 g once daily for 7 days
Number of subjects: 101
Study 2292207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g as a single preoperative dose
Number of subjects: 200
Study 2292207 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1 g preoperative dose plus 9 postoperative doses every 8 h for 3 days
Number of subjects: 200
Study 7407745 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (6 grams daily)
Number of subjects: 0
Study 7407745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 grams daily)
Number of subjects: 0
Study 31698965 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 31698965 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 31551225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide polysulfate ointment combined with desonide ointment
Number of subjects: 180
Study 31551225 — intervention group
Group type: COMPARATOR
Intervention: Desonide ointment only
Number of subjects: 180
Study 28125598 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 7
Study 28125598 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid therapy
Number of subjects: 7
Study 29046015 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg bolus dose and infusion at 10 mg/kg/h)
Number of subjects: 100
Study 29046015 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 100
Study 24631042 — intervention group
Group type: EXPERIMENTAL
Intervention: A manihot (huangkui capsule), 2.5 g, 3 times per day
Number of subjects: 417
Study 24631042 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium, 50 mg/d
Number of subjects: 417
Study 24631042 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (A manihot + losartan)
Number of subjects: 417
Study 23115404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly zolpidem, 10 mg (5 mg for patients > 60 yrs)
Number of subjects: 91
Study 23115404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 19569018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate (Pi) load (100 mmol) in NTS group
Number of subjects: 84
Study 19569018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate (Pi) load (100 mmol) in CNT group
Number of subjects: 84
Study 19569018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate (Pi) load (100 mmol) in NTS and CNT groups
Number of subjects: 84
Study 19569018 — intervention group
Group type: COMPARATOR
Intervention: NTS and CNT groups compared to GK
Number of subjects: 84
Study 17563571 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated GFR (MDRD formula)
Number of subjects: 15245
Study 17563571 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated creatinine clearance (Cockcroft-Gault)
Number of subjects: 15245
Study 15109973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain group (n = 54) - received painful electrocutaneous stimuli
Number of subjects: 107
Study 15109973 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 53) - received non-painful vibrotactile targets
Number of subjects: 107
Study 11473947 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix) during ovarian stimulation for IVF or ICSI
Number of subjects: 333
Study 9459533 — intervention group
Group type: COMPARATOR
Intervention: 0900 hours
Number of subjects: 23
Study 9459533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1400 hours
Number of subjects: 23
Study 9459533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 hours
Number of subjects: 23
Study 9459533 — intervention group
Group type: EXPERIMENTAL
Intervention: 0900 hours to 1800 hours
Number of subjects: 23
Study 8065723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment in orabase
Number of subjects: 55
Study 8065723 — intervention group
Group type: COMPARATOR
Intervention: 0.05% fluocinonide ointment in orabase
Number of subjects: 55
Study 8065723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications (clobetasol propionate and fluocinonide)
Number of subjects: 55
Study 8065723 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidiasis observed in patients
Number of subjects: 55
Study 2115186 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 (6 ng/kg/min over 8 hours daily for 5 consecutive days)
Number of subjects: 108
Study 2115186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 76841 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 208
Study 76841 — intervention group
Group type: COMPARATOR
Intervention: Control (Untreated)
Number of subjects: 208
Study 76841 — intervention group
Group type: COMPARATOR
Intervention: Control (Previously unscarred kidneys)
Number of subjects: 208
Study 76841 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of re‐existing kidney scars
Number of subjects: 208
Study 76841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 208
Study 31829267 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal physical activity optimism at 4 months
Number of subjects: 259
Study 31829267 — intervention group
Group type: EXPERIMENTAL
Intervention: Home physical activity equipment at 9 months
Number of subjects: 259
Study 31829267 — intervention group
Group type: EXPERIMENTAL
Intervention: Time outdoors - middle tertile at 9 months
Number of subjects: 259
Study 31829267 — intervention group
Group type: EXPERIMENTAL
Intervention: Time outdoors - highest tertile at 9 months
Number of subjects: 259
Study 31829267 — intervention group
Group type: EXPERIMENTAL
Intervention: Time free to move about - highest tertile at 19 months
Number of subjects: 259
Study 31829267 — intervention group
Group type: EXPERIMENTAL
Intervention: Time with older children - middle tertile at 19 months
Number of subjects: 259